[go: up one dir, main page]

EP3360547A1 - Bakterizide und viruzide pharmazeutische zusammensetzung - Google Patents

Bakterizide und viruzide pharmazeutische zusammensetzung Download PDF

Info

Publication number
EP3360547A1
EP3360547A1 EP16853143.2A EP16853143A EP3360547A1 EP 3360547 A1 EP3360547 A1 EP 3360547A1 EP 16853143 A EP16853143 A EP 16853143A EP 3360547 A1 EP3360547 A1 EP 3360547A1
Authority
EP
European Patent Office
Prior art keywords
composition
nsaid
ibuprofen
concentration
ibu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16853143.2A
Other languages
English (en)
French (fr)
Other versions
EP3360547A4 (de
EP3360547B1 (de
Inventor
Luis Alberto ARGAÑARÁS
Adrian Javier MUÑOZ
Roxana Valeria ALASINO
Ariel Gustavo GARRO
Dante Miguel Beltramo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimica Luar SRL
Original Assignee
Quimica Luar SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Luar SRL filed Critical Quimica Luar SRL
Publication of EP3360547A1 publication Critical patent/EP3360547A1/de
Publication of EP3360547A4 publication Critical patent/EP3360547A4/de
Application granted granted Critical
Publication of EP3360547B1 publication Critical patent/EP3360547B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the present invention relates to pharmaceutical compositions for the treatment of pulmonary diseases and of epithelial tissue, such as cystic fibrosis.
  • this invention is a composition meant for topic use or nebulisations.
  • Non-steroidal anti-inflammatory drugs are a heterogeneous group of drugs which share their therapeutical action (analgesic, anti-inflammatory and antipyretic effect) but differ in their relative toxicity and efficacy.
  • NSAIDs are relatively safe are drugs, when administered in suitable doses and to selected patients they may present potentially severe adverse effects and interactions.
  • the side effects caused by NSAIDs affect various organs, but those generated at the gastrointestinal level are the most frequent ones.
  • About 2-3% of patients taking NSAIDs for a year develop gastrointestinal complications such as bleeding, or upper or lower perforation. Over that period, 5-10% desarrollan ⁇ lceras sintomáticas y un 30-50% desarrollan dispepsia que requiere atenconstrutive [ Lanas, A., Pique, J.M., Ponce, J., Gastroenterol. Hepatol., 24, 22 (2001 ); Gastroenterol. Hepatol., 24, 134 (2001).2 ].
  • Ibuprofen is considered a non-steroidal anti-inflammatory agent (NSAID) frequently used as antipyretic and for the symptomatic relief of headache (cluster), dental pain, muscle pain or myalgia, menstrual discomfort, mild neurological pain, and post-surgical pain. It is also used to treat inflammatory conditions such as those present in arthritis, rheumatoid arthritis and gouty arthritis. Generally, the recommended adult dose is about 1200 mg daily. However, under medical supervision, the maximum amount of ibuprofen for adults is 800 mg per dose or 3200 mg per day.
  • NSAID non-steroidal anti-inflammatory agent
  • Symptoms are an excess of action and include abdominal pain, nausea, vomiting, dizziness, drowsiness, headache, tinnitus and nystagmus. Symptoms may be rarely more severe, being some of them gastrointestinal bleeding, seizures, metabolic acidosis, hyperkalemia, hypotension, bradycardia, tachycardia, atrial fibrillation, coma, liver failure, acute renal failure, cyanosis, respiratory depression and cardiac arrest.
  • Ibuprofen in structure, is a substantially water-insoluble molecule. It solubilizes less than 1 mg in 1 mL of water ( ⁇ 1 mg / mL).
  • the form of administration of ibuprofen for the treatment of all the cases mentioned above is always in tablets or soft capsules in which ibuprofen is found in protonated form. Therefore, such protonated form renders ibuprofen a markedly water-insoluble molecule.
  • ibuprofen is soluble in organic solvents such as ethanol or acetone.
  • Ibuprofen may be solubilised in water by removing the proton by some cation.
  • an aqueous solution up to concentrations of 1 M pH 7.0 - 8.5, titrating ibuprofen with alkaline solutions of sodium hydroxide, potassium hydroxide, magnesium hydroxide may be prepared, or else diethanolamine, tris(hydroxymethyl)aminomethane (THAM) or arginine, lysine or histidine may be added.
  • THAM tris(hydroxymethyl)aminomethane
  • arginine arginine
  • lysine or histidine may be added.
  • CMC critical micelle concentration
  • ibuprofen is largely bound to plasma albumin, although in babies, this appears to be significantly lower (95%) compared with adult plasma (99%). Ibuprofen competes with bilirubin binding to albumin. Especially in the serum of newborn babies, this could result in the increased free fraction of bilirubin at high concentrations of ibuprofen.
  • US20120115897 A1 describes the formation of a complex between ibuprofen and derivatives of esters of ascorbic acid and shows that this formulation can enhance water solubility, facilitating intravenous administration reducing application time, thereby lowering its undesired effect at the gastrointestinal level, increasing its penetration into the blood-brain barrier and it can be applied in various diseases such as arthritis, multiple sclerosis, cystic fibrosis, and pneumonia in the treatment of patent ductus arteriosus in premature infants, problems of cerebral hypoxia and certain cancers.
  • ibuprofen in methanol, which allows precipitation in the dilution of the solutions.
  • this NSAID is commonly used in injectable form, which results in two problems. The first is that sodium ibuprofen has a strong hemolytic effect, and second is that ibuprofen rapidly interacts with albumin, the major plasma protein that when forming a complex strongly inhibits its bactericidal activity as it is demonstrated in the studies herein, where it is clearly shown that, depending on the concentration of albumin present in the medium, the bactericidal activity of ibuprofen decreases.
  • US 20130178448 A1 discloses a formulation of oral administration of ibuprofen which is in the presence of different types of lipids such as triglycerides or other fatty acids and alcohol, which can be administered as a liquid or tablets to be ingested orally by animals so that they may reach high levels of ibuprofen in blood in the treatment of lung diseases. It is herein demonstrated that when ibuprofen is solubilised in a triglyceride emulsion, as it happens in its interaction with albumin, it completely loses its bactericidal activity.
  • lipids such as triglycerides or other fatty acids and alcohol
  • ibuprofen when solubilised in water it acquires surfactant properties. Therefore, it can interact with lipid membranes affecting its stability.
  • the interaction between ibuprofen and lipids and also its toxicity depends on the aggregation state of ibuprofen. It has been mentioned that at concentrations above its CMC, ibuprofen can damage the integrity of lipid membranes.
  • the present invention provides a composition that can be administered by nebulisation to treat cystic fibrosis, which presents an unexpected and surprising effect by acting as a bactericide for type Gram + and Gram- bacteria, especially by inhibiting bacteria such as P. aeruginosa, S. aureus, B cepacia and also having virucidal effect on those lipid-enveloped viruses.
  • the composition of the present invention is very simple and its side effects are negligible, compared with the continuous use of common antibiotics for the treatment of this disease.
  • One of the technical effects of the present invention is that the bactericidal effect of ibuprofen increased 5 times for being in hypertonic NaCl solution, as it can be seen in Example 11 herein.
  • ibuprofen above and especially below its critical micelle concentration (CMC), to destabilize membranes of different Gram + and Gram- bacteria and lipid-enveloped viruses, affecting their biological activity, allowing redefining, thanks to the present invention, ibuprofen as a bactericidal and virucidal agent, in combination with a saline solution.
  • CMC critical micelle concentration
  • the bactericidal and virucidal pharmaceutical composition to be applied to epithelial tissue, such as lung, nose and mouth, the main object of the present invention, comprises an anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM solubilised in saline solution, preferably hypertonic comprising a concentration of between 0.3 and 2 Molar NaCl can be CIK; more preferably between 0.4 and 1, 1 Molar NaCl;even more preferably between 0.9 and 1, 05 Molar NaCl.
  • NSAID anti-inflammatory drug
  • Its administration form is selected from the group comprised by inhalation, nebulisation, mouthwash and topical administration.
  • said anti-inflammatory drug preferably comprises a concentration between 5 and 180 mM; more preferably less than 180 mM; even more preferably between 5 and 50 mM.
  • said non-steroidal anti-inflammatory is arylpropionic selected from the group comprised by ibuprofen, naproxen, flurbiprofen, ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, acetylated salicylates, non-acetylated salicylates, and combinations thereof; preferably ibuprofen.
  • composition comprises a pH in aqueous solution between 6.0 and 8.5; preferably between 7.0 and 8.0; more preferably between 7.5 and 7.9.
  • the present invention may be embodied either in liquid or as a powder or lyophilised by drying or lyophilisation respectively from the hypertonic aqueous solution of said pharmaceutical composition.
  • the present invention further comprises an anesthetic agent selected from the group comprised by xylocaine, lidocaine, carticaine, mepivacaine and mixtures thereof.
  • the present invention is a pharmaceutical composition for the treatment of cystic fibrosis in nebulised application to reach the lungs, as well as for the treatment of viral infections Herpes simplex type, applied to affected skin. It can also be used as a bactericidal mouthwash.
  • said pharmaceutical composition is in the absence of usual antibiotics for this disease.
  • antibiotics include among others, colistimethate sodium, tobramycin, ciprofloxacin, lysine, levofloxacin, ciprofloxacin aztreonam, fosfomycin, amphotericin B, vancomycin, gentamicin, ceftazidime, ampicillin and amikacin and mixtures thereof.
  • said composition further comprises said usual antibiotics.
  • the process of manufacturing said bactericidal and virucidal pharmaceutical composition to be applied on epithelial tissues, such as pulmonary, nasal and oral tissue, another object of the present invention comprises the following steps:
  • said process further comprises the following step: E. the filtered solution of step D. is lyophilised;
  • step E when applied either to be vehiculated to the lungs by nebuliser or to be applied to the mouth as a mouthwash, the lyophilised composition of step E. is resuspended in water or in a 5% glucose solution.
  • the present invention provides a bactericidal and virucidal pharmaceutical composition to be applied on epithelial tissues, such as pulmonary, nasal and oral tissue, comprising a non-steroidal anti-inflammatory drug (NSAID) and a salt.
  • NSAID non-steroidal anti-inflammatory drug
  • a salt is selected from the group comprising sodium chloride, potassium and combinations thereof.
  • such composition comprises a pharmaceutical formulation to be diluted in water in the absence of any other component.
  • it comprises a pharmaceutical formulation for the treatment of cystic fibrosis.
  • it comprises a pharmaceutical formulation for the treatment of Herpes Simplex.
  • the bactericidal pharmaceutical composition which also has virucidal effects, which is to be applied on epithelial tissues, such as pulmonary, nasal and oral tissue
  • the main object of the present invention comprises a non-steroidal anti-inflammatory drug (NSAID) and a salt; wherein said NSAID is in a concentration between 5 and 500 mM and solubilised in saline solution of said salt.
  • said saline solution is preferably hypertonic comprising a concentration of between 0.3 and 2 Molar of a salt that is preferably NaCl, but can be any salt suitable for human consumption such as potassium chloride; more preferably between 0.4 and 1, 1 Molar NaCl; even more preferably between 0.9 and 1, 05 Molar NaCl.
  • non-steroidal anti-inflammatory drug preferably comprises a concentration between 5 and 180 mM; more preferably less than 180 mM; even more preferably between 5 and 50 mM.
  • said non-steroidal anti-inflammatory agent is selected from the group comprised by ibuprofen, naproxen, flurbiprofen, ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, acetylated salicylates, non-acetylated salicylates, and combinations thereof; preferably ibuprofen.
  • said composition comprises a pH in aqueous solution between 6.0 and 8.5; preferably between 7.0 and 8.0; more preferably between7.5 and 7.9.
  • said pharmaceutical composition comprises ibuprofen or sodium ibuprofen in a concentration of 50 mM in a hypertonic saline solution 1 M of NaCl.
  • the present invention may be prepared either in liquid state or as a powder or lyophilised by drying or lyophilisation, respectively from the hypertonic aqueous solution of said pharmaceutical composition. Both the drying process and the lyophilisation of pharmaceutical compositions is well known in the prior art, therefore providing further details on the subject is not considered necessary.
  • the present invention further comprises an anesthetic agent.
  • anesthetic agent can be any of the accepted ones for pharmaceutical use.
  • anesthetics preferred for the present invention, the following can be mentioned: xylocaine, lidocaine, carticaine, mepivacaine and the mixtures thereof.
  • the present invention is a pharmaceutical composition which is useful for the treatment of cystic fibrosis in nebulised application to reach the lungs.
  • the present invention has advantages that had never been reported before, since with very low doses of NSAIDs not only anti-inflammatory but also bactericidal and virucidal effects are achieved, without generating resistant mucus and acting even if it already exists.
  • the present invention is also applicable in the treatment of Herpes simplex type viral infections, applied to affected skin.
  • the present invention is also effective as bactericidal oral rinse.
  • the combination of ionic strength with the presence of NSAIDs at very low doses achieves a bactericidal and virucidal effect that has never been reported before.
  • using very low concentrations of NSAIDs results in a dramatic reduction of the common adverse effects of these anti-inflammatory drugs.
  • said pharmaceutical composition is free from the usual antibiotics for this disease.
  • antibiotics are, among others, colistimethate sodium, tobramycin, ciprofloxacin, lysine, levofloxacin, ciprofloxacin aztreonam, fosfomycin, amphotericin B, vancomycin, gentamicin, ceftazidime, ampicillin and amikacin and the mixtures thereof.
  • said composition further comprises said usual antibiotics.
  • the process of manufacturing said bactericidal and virucidal pharmaceutical composition for application on lung, nose and mouth epithelial tissues comprises the following steps:
  • said process further comprises the following step: F. the filtered solution of step E. in claim 11 is lyophilised;
  • step F when applied either to be vehiculated to reach the lungs by means of a nebuliser or to be applied to the mouth as a mouthwash, the lyophilised composition of step f. is resuspended in distilled water or in a 5% glucose solution.
  • tests were run on a non-nutritive liquid carrier (buffer solution) wherein the antimicrobial agent is mixed with quantified inocula of pure bacterial cultures. After different incubation times, the material is seeded on agar plates to perform quantification assays on the number of bacterias surviving the treatment.
  • buffer solution a non-nutritive liquid carrier
  • the antimicrobial agent is mixed with quantified inocula of pure bacterial cultures. After different incubation times, the material is seeded on agar plates to perform quantification assays on the number of bacterias surviving the treatment.
  • NSAIDs preferably ibuprofen
  • tests were conducted as described in Alasino et al in 2007.
  • the various strains of virus with lipid envelope are incubated with increasing amounts of ibuprofen for a period ranging between 60 and 120 minutes.
  • This material was then incubated with cultured cells which are susceptible to attack by these viruses, showing a marked cytopathic effect (cell aggregates (rosettes) or cell death) that can be detected by observation under the optical microscope.
  • the present invention provides a composition of ibuprofen sodium alone or associated with a hypertonic saline pH between 6.8 and 8.2, having bactericidal properties against different bacteria such as Pseudomonas aeruginosa , Burkhordelia cepacia, Pseudomonas fluorescens, Enterobacter aerogenes, Klebsiella pneumoniae, Escherichia coli, Bacillus subtilis (Gram +), Staphylococcus aureus (Gram +), Enterococcus faecalis (Gram +) and virucidal properties which produce the inactivation of those lipid-enveloped viruses such as, bovine diarrhea virus, Herpes types I and II, vesicular stomatitis virus, hepatitis C virus, varicella virus.
  • bactericidal properties against different bacteria such as Pseudomonas aeruginosa , Burkhordelia cepacia
  • composition of the present invention with bactericidal and virucidal properties may be used in the treatment of infectious diseases of the bacterial type that directly affect mucosa such as oral or pulmonary mucosa, or else viral diseases as infections by Herpes type I, on lips, mouth or vaginal level, as well as in the case of the cutaneous expression of Herpes virus type II.
  • the bactericidal properties of an IBU solution alone, preferably in combination with a hypertonic solution, is beneficial to treat bacterial infections, especially those at the lung level caused by bacteria such as P aeruginosa, which is capable of producing biofilms, as in the case of cystic fibrosis, a disease that is very difficult to cure.
  • the composition of the present invention can be in liquid form, which makes it likely to be applied by a standard nebulisation system.
  • Nebulisers are the devices of choice for pulmonary administration of drugs. Current nebulisers work by ultrasonic pulses applied to a solution meant to form a cloud where the drugs to be vehiculated are found. Patients breath in this cloud normally for several minutes until the solution is exhausted, normally 1 to 5 mL by nebulisation, which has some advantages as follows:
  • the advantage of this formulation against current antiseptic formulations lies in that those which use chlorhexidine eventually cause teeth coloring, while this does not happen with the use of ibuprofen.
  • the composition of the invention can be used for buccal or labial infections caused by Herpes Simplex Type I viruses since in addition to its antiviral effect it provides anti-inflammatory effect during treatment, a desired condition to reliever discomfort during infection.
  • composition of the invention comprises at least one bioactive agent such as NSAIDs solubilised in aqueous medium in addition to the classical anti-inflammatory property, in the present invention exhibits bactericidal and virucidal properties when said NSAID is formulated at a concentration below its critical micelle concentration and in the presence of saline solution.
  • bioactive agent such as NSAIDs solubilised in aqueous medium in addition to the classical anti-inflammatory property
  • the manufacturing process of said composition comprises for instance, the following steps:
  • Said NSAIDs may be selected from the group comprised by arylpropionic selected from the group comprised by ibuprofen, naproxen, flurbiprofen, ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, acetylated salicylates, non-acetylated salicylates, and combinations thereof.
  • arylpropionic selected from the group comprised by ibuprofen, naproxen, flurbiprofen, ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, indomethacin, meclofenamate, mefenamic acid,
  • Salts of said NSAIDs such as Na, I or K are preferred. Therefore, when adding sodium hydroxide solution is added, NSAID salt is formed.
  • sodium ibuprofen (IBU-Na) is used, for it presents greater solubility in aqueous solution than protonated ibuprofen (IBU-H).
  • composition of the present invention comprises powder NSAID, preferably sodium ibuprofen, and Na or K salt in a molar ratio of NSAID: salt of 1: 0.6 and 1: 400, preferably between 1: 10 and 1: 100.
  • This powder may be diluted in water to obtain the pharmaceutical formulation of the invention.
  • IBUPROFEN means ibuprofen in any of its forms.
  • PROTONATED IBUPROFEN is to be identified with the following name:
  • SODIUM IBUPROFEN also known as SODIUM IBUPROFENATE or IBUPROFEN SODIUM SALT shall be identified as IBU-Na herein.
  • This sodium ibuprofen can be free of water in mono hydrate or dihydrate form.
  • IBU-H solutions Solid ibuprofen is dissolved (20 g in pure ethanol up to 100 mL); this represents IBU-H 1M solution. Studies on the activity of these formulations use a solution that placed on the culture medium does not exceed 5% ethanol concentration which does not affect the viability of bacteria.
  • IBU-Na Solution Preparation IBU-Na stock solution is prepared by weighing 20 g of ibuprofen, adding water to 50 mL, and then adding enough NAHO 4M solution to reach a pH between 7 and 8; finally it is made up to 100 mL to a final concentration of 1 M Na-IBU.
  • Naproxen stock solution is prepared by weighing 23 g of Naproxen, adding water to 50 mL, and then adding enough NAHO 4M solution to achieve a pH between 7 and 8; finally it is made up to 100 mL to reach a final concentration of 1 M Naproxen.
  • compositions ranging from 1 to 100 mM of IBU-Na and hypertonic solutions, which present a final concentration of 1 M NaCl are obtained following the procedure described.
  • the procedures followed are the usual laboratory practices to perform dilutions.
  • Lyophilised commercial strains ATCC (KWIK-STIK MicroBioLogics) activated in tubes containing 10 mL of Brain Heart Infusion BHI (Biokar BK015HA) at 37 ° C for 24 hours were used.
  • Composition in g/L Brain and heart Infusion 17.5 • eptone 10 • Glucose 2 • Sodium chloride 5 • Disodium phosphate 2.5
  • IBU effectiveness testing at different concentrations, times of action, ionic strength, pH variations and various bacterial populations were performed; effective concentrations of commercial tobramycin antibiotic ( Figure 2 ) were also measured.
  • TTC triphenyltetrazolium of chloride
  • the medium composition in g/L is: Peptone 17.5 Starch 1.5 Meat extract 4 Agar 15
  • the medium was stored in thermostatic bath between 45-50 ° C because the seeding technique requires imbibing and integrating bacteria in the medium. Once solidified, the plates were incubated in inverted position for a set time of 24-48 hours prior to each count for the purposes of assessing the effective concentrations in each case and comparing with other treatments.
  • test results are shown with IBU-Na and IBU-H solutions at different molar increasing concentrations on a population of P. aeruginosa at an incubation time of 4 h at 37 ° C and subsequent seeding.
  • IBU [mM] P. aeruginosa UCC/mL ⁇ 10
  • IBU-Na IBU-H 0 (Control) 1,700,000 1,700,000 1 1,700,000 1,700,000 5 1,700,000 1,700,000 10 760,000 480,000 20 300,000 200,000 50 50 1000 100 10 10
  • results shown correspond to a test with IBU-Na solutions at different increasing molar concentrations on three populations of the same strain ( P. aeruginosa ) for an incubation time of 4 h at 37 ° C and subsequent plating.
  • IBU-Na [mM] P. aeruginosa (UFC/mL ⁇ 10) Population A Population B Population C 0 (Control) 200,000 20,000 2,000 1 200,000 20,000 2,000 5 150,000 17,000 1,800 10 100,000 3,500 800 20 20,000 400 50 30 500 40 10 40 100 10 10 50 10 10 10 10 100 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
  • IBU-Na [mM] P. aeruginosa count UCC/mL ⁇ 10.
  • IBU-Na acts as an antimicrobial agent in the range of physiological pH values.
  • IBU-Na Antimicrobial effect of IBU-Na at two test concentrations [50 and 100 mM] on the viability of Gram positive and negative bacterial strains during 4-hour contact at 37 ° C.
  • IBU-Na acts an antimicrobial agent on different bacterial strains (Gram positive and negative ones).
  • IBU-Na IBU-Na [mM] Colony count (UFC/mL ⁇ 10) Staphylococcus Burkhordelia Pseudomonas 0 (Control) 1,000,000 1,300,000. 1,700,000. 5 1,000,000 1,300,000 1,700,000 10 1,000,000 1,300,000 760,000 25 30,000 40,000 200,000 50 600 700 100 100 10 10 10
  • the present invention has an unexpected and surprising technical effect, by achieving an almost instant synergistic effect (in relation to other therapeutic options) that promotes the interaction of ibuprofen on microorganisms, and thus in just one minute achieving a dramatic decrease of the population of microorganisms typical of cystic fibrosis.
  • LIPOVENOSTM has no effect on the inoculum at the concentrations tested.
  • LIPOVENOS initial preincubation at different concentrations with IBU-Na 20 [mM] at room temperature for 1 hour. It was subsequently mixed with bacteria to begin a treatment of 4 hours at 37 ° C. LIPOVENOS(%) + Ibu 20 mM P. aeruginosa (UFC/mL ⁇ 10) Control * 1,000,000 LIPO 10% +IBU 20 Mm 1,000,000 LIPO 5% +IBU 20 Mm 1,000,000 LIPO 2.5% +IBU 20 Mm 1,000,000 * LIPOVENOS 10%, without IBU-Na
  • This example shows an assay to assess a formulation of tobramycin antibiotic in the presence of 1 M NaCl solution on a population of P. aeruginosa for 4 h at 37 ° C. Tobramycin [mM] with CINa (1M) P. aeruginosa (UFC/mL ⁇ 10) 0 1,000,000 0.25 400,000 1 10 5 10 10 10
  • enveloped viruses having a lipid envelope.
  • Kidney cells from African green monkey (Vero) (ATCC CCL-21), Madin Darby bovine kidney (MDBK) (ATCC CCL-22) cells and human cells from epithelial larynx tumor (Hep 2) (ATCC CCL-23) were propagated in minimal essential medium (MEM) supplemented with 10% fetal bovine serum irradiated containing 10000 IU of penicillin and 2 mM glutamine.
  • MEM minimal essential medium
  • the BVDV bovine diarrhea virus was provided by INTA Castelar, and it was propagated in MDBK cell monolayers.
  • the vesicular stomatitis virus (VSV) (ATCC VR-158) and Herpes Simplex 1 virus (HSV) were propagated in VERO cells.
  • Rubella virus strain (MV) was obtained from the Rouvax commercial vaccine (Paster Merieux. France) was propagated in Hep-2 cells.
  • the Herpes Simplex Virus (HSV) was provided by the Institute of Virology of the UNC, Universidad Nacional de Córdobo.
  • Viruses were propagated using cells that are susceptible of infection, which were grown at 37 °C, until complete destruction of the cell monolayer.
  • Cell-associated viruses were extracted using three freeze-thaw cycles of the bottles that contained the cells. The material was centrifuged at 3000 x g for 15 minutes and the supernatant was fractionated and stored at -70 °C until use.
  • infectivity virus activity was determined by the titration method (by dilution 1/10) in 96-well plates (NUNC Life Technologies, Rockville, MD, USA), applying the criterion of measuring the cytopathic effect on cells (aggregation and cell death) and therefore positive or negative is determined.
  • 1/10 serial dilutions of viruses were prepared in quadruplicate and incubated for 60 minutes at 37 °C stirring gently at different concentrations of ibuprofen ranging from 1 to 50 mM. After this period, the virus solution with ibuprofen is incubated in the presence of the cells and is also allowed to stand for 60 min. at 37 ° C in order to allow the adsorption of the virus on the cells so they can exert their cytopathic effect. Then 150 uL of maintenance medium is added to each well without removing the inoculum.
  • Incubation was carried out at 37 °C in a stove containing 5% atmosphere of C02, 90% relative humidity for 3 days the case of HSV and VSV virus or up to 7 or 8 days for MV and BVDV virus, to allow sufficient time to detect the appearance of a potential cytopathic effect.
  • TCID50 mL-1 The so called Infectious Dose of cell culture 50% (TCID50 mL-1) was calculated by the Reed-Muench method of analysis ( Reed U, H. Munch, Am. J. Hygiene 1938 27, 493 .) for wells infected by positive viruses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP16853143.2A 2015-10-05 2016-10-04 Bakterizide pharmazeutische zusammensetzung enthaltend ibuprofen Active EP3360547B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP150103203A AR102172A1 (es) 2015-10-05 2015-10-05 Una composición farmacéutica bactericida y virucida
PCT/ES2016/070702 WO2017060550A1 (es) 2015-10-05 2016-10-04 Una composición farmacéutica bactericida y virucida

Publications (3)

Publication Number Publication Date
EP3360547A1 true EP3360547A1 (de) 2018-08-15
EP3360547A4 EP3360547A4 (de) 2019-08-21
EP3360547B1 EP3360547B1 (de) 2022-07-13

Family

ID=58488060

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16853143.2A Active EP3360547B1 (de) 2015-10-05 2016-10-04 Bakterizide pharmazeutische zusammensetzung enthaltend ibuprofen

Country Status (8)

Country Link
US (4) US10973787B2 (de)
EP (1) EP3360547B1 (de)
AR (1) AR102172A1 (de)
BR (1) BR112018006431A2 (de)
ES (1) ES2928399T3 (de)
PL (1) PL3360547T3 (de)
PT (1) PT3360547T (de)
WO (1) WO2017060550A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946144A4 (de) * 2019-04-04 2023-01-04 The Texas A&M University System Abgabevorrichtungen zur lokalisierten abgabe von antimikrobiellen, entzündungshemmenden und antioxidativen wirkstoffen
WO2023100127A1 (en) * 2021-12-01 2023-06-08 Quimica Luar S.R.L. Pharmaceutical composition comprising ibuprofen and arginine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102172A1 (es) * 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
US12324853B2 (en) * 2020-08-10 2025-06-10 Quimica Luar S.R.L. Methods for treating respiratory viral infections
CN112843092B (zh) * 2021-01-20 2022-05-10 朱有建 免疫细胞在治疗疾病中的应用及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184013A (ja) 1984-03-01 1985-09-19 Yoshitomi Pharmaceut Ind Ltd 点眼剤
RU2148402C1 (ru) * 1994-03-15 2000-05-10 Сендзю Фармасьютикал Ко., Лтд. Способ стабилизации пранопрофена (варианты) и стабильный водный препарат на основе пранопрофена
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US20030211173A1 (en) 2002-05-08 2003-11-13 Veach Tom C. Lubrication composition
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
AU2005235308B2 (en) * 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US7186186B2 (en) * 2005-01-22 2007-03-06 Takeo Imahata Game apparatus having a ball drop mechanism
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
CN101550119B (zh) 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
BRPI0925099A2 (pt) * 2009-06-24 2018-10-16 Strategic Science & Tech Llc composição tópica contendo ibuprofeno
GB2477590A (en) 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
NZ588686A (en) * 2011-01-20 2013-07-26 Bayer New Zealand Ltd Injectable composition comprising an NSAID and an antibiotic in a non-aqueous solvent for treating a microbial infection in a mammary gland
CN102138893A (zh) * 2011-03-21 2011-08-03 陕西宏府怡悦制药有限公司 制备赖氨洛芬氯化钠注射液的工艺方法及其用途
MY183615A (en) * 2011-06-17 2021-03-03 Berg Llc Inhalable pharmaceutical compositions
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
AR102172A1 (es) 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
US20210393554A1 (en) 2018-11-15 2021-12-23 Bluewillow Biologics, Inc. Nanoemulsion compositions having enhanced permeability
US12324853B2 (en) 2020-08-10 2025-06-10 Quimica Luar S.R.L. Methods for treating respiratory viral infections

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946144A4 (de) * 2019-04-04 2023-01-04 The Texas A&M University System Abgabevorrichtungen zur lokalisierten abgabe von antimikrobiellen, entzündungshemmenden und antioxidativen wirkstoffen
WO2023100127A1 (en) * 2021-12-01 2023-06-08 Quimica Luar S.R.L. Pharmaceutical composition comprising ibuprofen and arginine

Also Published As

Publication number Publication date
US20180296509A1 (en) 2018-10-18
BR112018006431A2 (pt) 2018-12-11
EP3360547A4 (de) 2019-08-21
AR102172A1 (es) 2017-02-08
US20240325332A1 (en) 2024-10-03
US20250213511A1 (en) 2025-07-03
US20210275476A1 (en) 2021-09-09
PL3360547T3 (pl) 2022-12-19
WO2017060550A1 (es) 2017-04-13
US11925612B2 (en) 2024-03-12
US10973787B2 (en) 2021-04-13
EP3360547B1 (de) 2022-07-13
PT3360547T (pt) 2022-10-18
US12171733B2 (en) 2024-12-24
ES2928399T3 (es) 2022-11-17

Similar Documents

Publication Publication Date Title
US12171733B2 (en) Bactericidal and virucidal pharmaceutical composition
US6709681B2 (en) Acidified nitrite as an antimicrobial agent
US8747872B2 (en) Nanoemulsion therapeutic compositions and methods of using the same
EP3223833B1 (de) Vorbeugung und behandlung von mikrobiellen infektionen
BR122019015601B1 (pt) produto, substrato, composição farmacêutica e uso de um produto
CN106573944A (zh) 作为抗菌剂的金(i)‑膦化合物
US20220117924A1 (en) Compositions of Glycerol and /or Non-Toxic Amino Acids for Inhibiting and Destroying Biofilm, including Related Methods
JP6941889B2 (ja) インサイチュゲル形成医薬組成物および副鼻腔疾患のためのその使用
WO2016131100A1 (en) Methods of treating infectious diseases
TW200526235A (en) Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
JP2013082752A (ja) フルニソリド含有粘膜適用組成物
US9913801B2 (en) Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione
EP0310476B1 (de) Für mindestens einzellige Lebewesen inhibitierende oder zerstörende F- und Li+ enthaltende Zusammensetzung
WO2021198940A1 (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
CN107848980A (zh) 抑制多药耐受微生物生长的组合物和方法
JP5019923B2 (ja) プラノプロフェン含有医薬組成物
EP3866775B1 (de) Cysteamin zur verwendung in der behandlung von lungenerkrankungen
US20250049733A1 (en) Pharmaceutical composition for the treatment of infectious respiratory diseases caused by influenza and sars-cov-2, among others
García Canclini et al. Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution
EP4091608A1 (de) Zusammensetzung mit antiviraler wirkung
WO2023100836A1 (ja) 医薬組成物
JP2020502096A (ja) 抗バクテリア剤（ａｎｔｉｂａｃｔｅｒｉａｌ ａｇｅｎｔ）として使用するためのｎ−アセチルシステイン
JP2000229863A (ja) 咽頭疾患用組成物
EA043054B1 (ru) N-ацетилцистеин для применения в качестве антибактериального агента
BR112019011708B1 (pt) Uso de n-acetilcisteína

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190724

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20190716BHEP

Ipc: A61P 31/22 20060101ALI20190716BHEP

Ipc: A61K 45/06 20060101ALI20190716BHEP

Ipc: A61K 33/14 20060101ALI20190716BHEP

Ipc: A61P 31/12 20060101ALI20190716BHEP

Ipc: A61P 31/04 20060101ALI20190716BHEP

Ipc: A61K 31/192 20060101AFI20190716BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200706

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101ALI20220119BHEP

Ipc: A61P 31/04 20060101ALI20220119BHEP

Ipc: A61P 31/22 20060101ALI20220119BHEP

Ipc: A61P 31/12 20060101ALI20220119BHEP

Ipc: A61P 11/00 20060101ALI20220119BHEP

Ipc: A61K 45/06 20060101ALI20220119BHEP

Ipc: A61K 33/14 20060101ALI20220119BHEP

Ipc: A61K 31/192 20060101AFI20220119BHEP

INTG Intention to grant announced

Effective date: 20220204

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BELTRAMO, DANTE MIGUEL

Inventor name: GARRO, ARIEL GUSTAVO

Inventor name: ALASINO, ROXANA VALERIA

Inventor name: MUNOZ, ADRIAN JAVIER

Inventor name: ARGANARAS, LUIS ALBERTO

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016073540

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1503908

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220815

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3360547

Country of ref document: PT

Date of ref document: 20221018

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20221011

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2928399

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221117

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220401939

Country of ref document: GR

Effective date: 20221109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221013

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1503908

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221113

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016073540

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

26N No opposition filed

Effective date: 20230414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221004

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220713

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20240918

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240920

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240919

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240919

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240925

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20241029

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20241028

Year of fee payment: 9

Ref country code: GR

Payment date: 20241029

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20241028

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20241025

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20241021

Year of fee payment: 9

Ref country code: ES

Payment date: 20241119

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20241027

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20241101

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251026

Year of fee payment: 10